Project description:Our goal was to find correlations between gene expression patterns and impaired vascular pathophysiolgy in rheumatoid arthritis Patients with rheumatoid arthritis were recruited and venous blood samples were collected, then peripheral blood mononuclear cells were separated. After RNA isoltaion, we used Affymetrix PrimeView arrays to obtain whole gene expression data.
Project description:This SuperSeries is composed of the following subset Series: GSE20680: Whole Blood Cell Gene Expression Profiling in Patients with Coronary Artery Disease from the Cathgen Registry GSE20681: Whole Blood Cell Gene Expression Profiling in Patients with Coronary Artery Disease from the PREDICT Trial Refer to individual Series
Project description:Gene expression profiling of peripheral blood cells from patients with rheumatoid arthritis (RA)/ systemic lupus erythematosus (SLE)/ polyarticular type juvenile idiopathic arthritis (polyJIA)/ systemic-onset JIA (sJIA) vs healthy children (HC) and healthy individual (HI).
Project description:Approximately 30% of rheumatoid arthritis patients achieve inadequate response to anti-TNF biologics. In this study, we sought to identify a blood gene expression biomarker correlating with 12-week response to infliximab in patients with moderate to severe disease. Response was assessed using dynamic contrast-enhanced MRI imaging of the wrist. Baseline whole blood samples from 59 patients were collected as part of a placebo-controlled clinical study of infliximab in rheumatoid arthritis. Samples were profiled by Affymetrix microarray and correlation between gene expression and 12-week response was assessed. DAS28 (Disease Activity Score including a 28-joint count)
Project description:Objective: We performed whole-blood transcriptomic profiling for patients with rheumatoid arthritis (RA) who received rituximab (RTX). We aimed to identify a molecular signature that could predict the clinical response to RTX and transcriptomic changes after RTX therapy.
Project description:Whole blood (paxgene) gene expression was measured using Affymetrix microarray from 377 individuals with rheumatoid arthritis. RA patient samples were collected from a phase III clinical trial of golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy (GO-FURTHER) according to trial protocol approved by local Institutional Review Board. A subset of subjects from the entire trial population at baseline (i.e., 377 subjects before golimumab treatment) was utilized. All patients consented to genetic and transcriptomics analyses.
